(3-methoxy-benzyl)[7-(1H-pyrazol-4-yl)benzo[1,2,4]triazin-3-yl]amine | 1257089-19-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (3-methoxy-benzyl)[7-(1H-pyrazol-4-yl)benzo[1,2,4]triazin-3-yl]amine
• 英文别名: N-[(3-methoxyphenyl)methyl]-7-(1H-pyrazol-4-yl)-1,2,4-benzotriazin-3-amine
• CAS: 1257089-19-2
• 化学式: C₁₈H₁₆N₆O
• 分子量: 332.365
• InChiKey: MBORSJRGCFITBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  88.6
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE<br/>[FR] BENZOTRIAZINES ET QUINOXINALINES SUBSTITUÉES COMME INHIBITEURS DE LA P7OS6 KINASE
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2010136755A1

  公开（公告）日：2010-12-02

  The invention provides compounds of the formula (1): or salts or tautomers thereof; wherein X1 is N or N+(O ); X2 is N or CH; Q is a C1-3 alkylene group; R1 is selected from hydrogen, C1-4 hydrocarbyl and hydroxy-C2-4 hydrocarbyl; R2, R3 and R4 are the same or different and each is selected from hydrogen, fluorine, chlorine and methyl; Ar1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring and Ar2 is an optionally substituted monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S. The compounds of formula (1) are inhibitors of p70S6 kinase and are useful in the treatment of proliferative diseases.

  该发明提供了式（1）的化合物或其盐或互变异构体；其中X1为N或N+（O-）；X2为N或CH；Q为C1-3烷基基团；R1从氢、C1-4烃基和羟基-C2-4烃基中选择；R2、R3和R4相同或不同，每个从氢、氟、氯和甲基中选择；Ar1为含有0、1或2个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员芳基或杂芳基环，或者是一个萘环；Ar2为含有1、2或3个来自O、N和S的杂原子环成员的可选择取代的单环5或6成员杂芳基环。式（1）的化合物是p70S6激酶的抑制剂，可用于治疗增殖性疾病。
• [EN] MODULATORS OF THE P70S6 KINASE FOR USE IN THE TREATMENT OF BRAIN DISORDERS AND TRIPLE-NEGATIVE BREAST CANCER<br/>[FR] MODULATEURS DE LA P70S6 KINASE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES CÉRÉBRAUX ET DU CANCER DU SEIN TRIPLE NÉGATIF
  申请人：SENTINEL ONCOLOGY LTD

  公开号：WO2016131776A1

  公开（公告）日：2016-08-25

  The invention provides compounds for use in the treatment of a disease or condition selected from brain disorders and triple-negative breast cancer, the compounds being of the formula (1) or a salt or tautomer thereof; wherein: X1 is N or N+(O'); X2 is N or CH; Q is selected from a C1-3 alkylene group, cyclopropane-1,1-diyl and cyclobutane- 1,1-diyl; R1 is selected from hydrogen and C1-4 alkyl;R2, R3 and R4 are the same or different and each is selected from hydrogen and fluorine; Ar1 is a benzene, thiophene, naphthyl or pyridine ring optionally substituted with 1, 2 or 3 substituents selected from fluorine; chlorine; bromine; CM hydrocarbyl; C1-4 hydrocarbyloxy; trifluoromethyl; difluoromethyl; cyano; trifluoromethoxy; difluoromethoxy; Ar2 is a monocyclic 5- or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S and being optionally substituted with 1, 2 or 3 substituents selected from fluorine; C1-4 hydrocarbyl; amino; mono-C1-4 hydrocarbylamino and di-C1-4 hydrocarbylamino; and wherein, in each substituent consisting of or containing C1-4 hydrocarbyl, the C1-4 hydrocarbyl is selected from C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, cyclopropyl, cyclobutyl and cyclopropylmethyl.

  该发明提供了用于治疗脑部疾病和三阴性乳腺癌等疾病或症状的化合物，该化合物为以下公式（1）或其盐或互变异构体；其中：X1为N或N+(O')；X2为N或CH；Q从C1-3烷基、环丙烷-1,1-二基和环丁烷-1,1-二基中选择；R1从氢和C1-4烷基中选择；R2、R3和R4相同或不同，每个从氢和氟中选择；Ar1为苯、噻吩、萘或吡啶环，可选择地取代1、2或3个从氟、氯、溴、CM烃基、C1-4烃基氧、三氟甲基、二氟甲基、氰、三氟甲氧基、二氟甲氧基中选择的取代基；Ar2为含有1、2或3个来自O、N和S的杂原子环成员的单环5-或6-成员杂环环，可选择地取代1、2或3个从氟、C1-4烃基、氨基、单C1-4烃基氨基和双C1-4烃基氨基中选择的取代基；在每个由或含有C1-4烃基的取代基中，C1-4烃基从C1-4烷基、C2-4烯基、C2-4炔基、环丙基、环丁基和环丙基甲基中选择。
• SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE
  申请人：Boyle Robert George

  公开号：US20120071478A1

  公开（公告）日：2012-03-22

  The invention provides compounds of the formula (1): or salts or tautomers thereof; wherein X 1 is N or N + (O − ); X 2 is N or CH; Q is a C 1-3 alkylene group; R 1 is selected from hydrogen, C 1-4 hydrocarbyl and hydroxy-C 2-4 hydrocarbyl; R 2 , R 3 and R 4 are the same or different and each is selected from hydrogen, fluorine, chlorine and methyl; Ar 1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring containing 0, 1 or 2 heteroatom ring members selected from O, N and S, or a naphthyl ring and Ar 2 is an optionally substituted monocyclic 5 or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S. The compounds of formula (1) are inhibitors of p70S6 kinase and are useful in the treatment of proliferative diseases.

  本发明提供公式（1）的化合物：或其盐或互变异构体；其中X1为N或N +（O-）; X2为N或CH; Q为C1-3烷基基团; R1选择自氢，C1-4烃基和羟基-C2-4烃基; R2，R3和R4相同或不同，且每个选择自氢，氟，氯和甲基; Ar1为含有0、1或2个杂环环成员（选自O，N和S）的可选择取代的单环5或6成员芳基或杂芳基环，或萘环；Ar2为含有1、2或3个杂环环成员（选自O，N和S）的可选择取代的单环5或6成员杂芳基环。公式（1）的化合物是p70S6激酶的抑制剂，可用于治疗增生性疾病。
• Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer
  申请人：SENTINEL ONCOLOGY LIMITED

  公开号：US10144726B2

  公开（公告）日：2018-12-04

  The invention provides compounds for use in the treatment of a disease or condition selected from brain disorders and triple-negative breast cancer, the compounds being of the formula (1): or a salt or tautomer thereof; wherein: X1 is N or N+(O−); X2 is N or CH; Q is selected from a C1-3 alkylene group, cyclopropane-1,1-diyl and cyclobutane-1,1-diyl; R1 is selected from hydrogen and C1-4 alkyl; R2, R3 and R4 are the same or different and each is selected from hydrogen and fluorine; Ar1 is a benzene, thiophene, naphthyl or pyridine ring optionally substituted with 1, 2 or 3 substituents selected from fluorine; chlorine; bromine; C1-4 hydrocarbyl; C1-4 hydrocarbyloxy; trifluoromethyl; difluoromethyl; cyano; trifluoromethoxy; difluoromethoxy; Ar2 is a monocyclic 5- or 6-membered heteroaryl ring containing 1, 2 or 3 heteroatom ring members selected from O, N and S and being optionally substituted with 1, 2 or 3 substituents selected from fluorine; C1-4 hydrocarbyl; amino; mono-C1-4 hydrocarbylamino and di-C1-4 hydrocarbylamino; and wherein, in each substituent consisting of or containing C1-4 hydrocarbyl, the C1-4 hydrocarbyl is selected from C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, cyclopropyl, cyclobutyl and cyclopropylmethyl.

  本发明提供了用于治疗选自脑疾病和三阴性乳腺癌的疾病或病症的化合物，这些化合物为式 (1)： 或其盐或同系物； 其中 X1 是 N 或 N+(O-)； X2 是 N 或 CH Q 选自 C1-3 烷基、环丙烷-1,1-二基和环丁烷-1,1-二基； R1 选自氢和 C1-4 烷基； R2、R3 和 R4 相同或不同，各自选自氢和氟； Ar1 是苯、噻吩、萘或吡啶环，可任选被 1、2 或 3 个取代基取代，这些取代基选 自氟、氯、溴、C1-4 烃基、C1-4 烃氧基、三氟甲基、二氟甲基、氰基、三氟甲氧基、 二氟甲氧基； Ar2 是单环的 5 或 6 元杂芳基环，含有 1、2 或 3 个选自 O、N 和 S 的杂原子环成员，并可选地被 1、2 或 3 个选自氟、C1-4烃基、氨基、单-C1-4烃基氨基和二-C1-4烃基氨基的取代基取代； 其中，在每个由 C1-4 碳氢基组成或含有 C1-4 碳氢基的取代基中，C1-4 碳氢基选自 C1-4 烷基、C2-4 烯基、C2-4 炔基、环丙基、环丁基和环丙基甲基。
• SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P70S6 KINASE
  申请人：Sentinel Oncology Limited

  公开号：EP2435423B1

  公开（公告）日：2014-10-15